Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus

Abstract

Confinement of transgene expression to target cells is highly desirable in gene therapy. Current strategies of transcriptional targeting to tumors usually rely on tissue-specific promoters to control gene expression. However, such promoters generally have much lower activity than the constitutive viral promoters. We have explored an alternative approach, using a strict-late viral promoter (UL38p) in the context of an oncolytic herpes simplex virus (HSV) for tumor-selective gene expression. As with many DNA viruses, the genomic transcription of HSV is a tightly regulated molecular cascade in which early and late phases of gene expression are separated by viral DNA replication. In particular, some of the late transcripts are categorized as strict-late, whose expression depends rigorously on the initiation of viral DNA replication. Our in vitro and in vivo characterization showed that in normal nondividing cells, where the oncolytic HSV has limited ability to replicate, the UL38p has minimal activity. However, in tumor or cycling cells where the virus can fully replicate, transgene expression from UL38p was almost as high as from the cytomegalovirus immediate-early promoter. These results suggest that delivery of therapeutic genes driven by UL38p through an oncolytic HSV may be an effective approach to gene therapy for malignant diseases.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Huber BE, Richards CA, Krenitsky TA . Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88: 8039–8043.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Vile RG, Hart IR . Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860–3864.

    CAS  PubMed  Google Scholar 

  3. Latham JP, Searle PF, Mautner V, James ND . Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334–341.

    CAS  PubMed  Google Scholar 

  4. Tanaka S et al. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein–Barr virus (EBV)-based plasmid vector carrying the CEA promoter. Cancer Gene Ther 2000; 7: 1241–1250.

    Article  CAS  PubMed  Google Scholar 

  5. Schuur ER et al. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996; 271: 7043–7051.

    Article  CAS  PubMed  Google Scholar 

  6. Koga S et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000; 11: 1397–1406.

    Article  CAS  PubMed  Google Scholar 

  7. Babiss LE, Friedman JM, Darnell JE . Cellular promoters incorporated into the adenovirus genome. Effect of viral DNA replication on endogenous and exogenous gene transcription. J Mol Biol 1987; 193: 643–650.

    Article  CAS  PubMed  Google Scholar 

  8. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science 1996; 274: 373–376.

    Article  CAS  PubMed  Google Scholar 

  9. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854–856.

    Article  CAS  PubMed  Google Scholar 

  10. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–943.

    Article  CAS  PubMed  Google Scholar 

  11. Wagner EK, Guzowski JF, Singh J . Transcription of the herpes simplex virus genome during productive and latent infection. Prog Nucleic Acid Res Mol Biol 1995; 51: 123–165.

    Article  CAS  PubMed  Google Scholar 

  12. Holland LE, Anderson KP, Shipman Jr C, Wagner EK . Viral DNA synthesis is required for the efficient expression of specific herpes simplex virus type 1 mRNA species. Virology 1980; 101: 10–24.

    Article  CAS  PubMed  Google Scholar 

  13. Flanagan WM et al. Analysis of the herpes simplex virus type 1 promoter controlling the expression of UL38, a true late gene involved in capsid assembly. J Virol 1991; 65: 769–786.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Johnson PA, Everett RD . DNA replication is required for abundant expression of a plasmid-borne late US11 gene of herpes simplex virus type 1. Nucleic Acids Res 1986; 14: 3609–3625.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Guzowski JF, Wagner EK . Mutational analysis of the herpes simplex virus type 1 strict late UL38 promoter/leader reveals two regions critical in transcriptional regulation. J Virol 1993; 67: 5098–5108.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Guzowski JF, Singh J, Wagner EK . Transcriptional activation of the herpes simplex virus type 1 UL38 promoter con-ferred by the cis-acting downstream activation sequence is mediated by a cellular transcription factor. J Virol 1994; 68: 7774–7789.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Goodart SA, Guzowski JF, Rice MK, Wagner EK . Effect of genomic location on expression of beta-galactosidase mRNA controlled by the herpes simplex virus type 1 UL38 promoter. J Virol 1992; 66: 2973–2981.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Saeki Y et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998; 9: 2787–2794.

    Article  CAS  PubMed  Google Scholar 

  19. Herrlinger U et al. HSV-1 infected cell proteins influence tetracycline-regulated transgene expression. J Gene Med 2000; 2: 379–389.

    Article  CAS  PubMed  Google Scholar 

  20. Schang LM, Phillips J, Schaffer PA . Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J Virol 1998; 72: 5626–5637.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000; 7: 859–866.

    Article  CAS  PubMed  Google Scholar 

  22. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867–874.

    Article  CAS  PubMed  Google Scholar 

  23. MacKie RM, Stewart B, Brown SM . Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357: 525–526.

    Article  CAS  PubMed  Google Scholar 

  24. Fu X, Zhang X . Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62: 2306–2312.

    CAS  PubMed  Google Scholar 

  25. Todryk S et al. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum Gene Ther 1999; 10: 2757–2768.

    Article  CAS  PubMed  Google Scholar 

  26. Bennett JJ et al. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 2000; 78: 166–174.

    Article  CAS  PubMed  Google Scholar 

  27. Schellingerhout D et al. Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 1998; 9: 1543–1549.

    Article  CAS  PubMed  Google Scholar 

  28. Wood M et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 1999; 6: 367–372.

    Article  CAS  PubMed  Google Scholar 

  29. Huard J, Goins WF, Glorioso JC . Herpes simplex virus type 1 vector mediated gene transfer to muscle. Gene Therapy 1995; 2: 385–392.

    CAS  PubMed  Google Scholar 

  30. Huard J et al. The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers. J Virol 1996; 70: 8117–8123.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Shenk T . Adenoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM (eds). Fields Virology. Lippincott Williams & Wilkins: Philadelphia, 1996, pp. 2111–2148.

    Google Scholar 

  32. Hawkins LK, Hermiston T . Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Therapy 2001; 8: 1142–1148.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Yoshinaga Saeki (Massachusetts General Hospital) for the generous gift of fHSV-delta-pac and Malcolm K Brenner for support and careful reading of the manuscript.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fu, X., Meng, F., Tao, L. et al. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus. Gene Ther 10, 1458–1464 (2003). https://doi.org/10.1038/sj.gt.3302029

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302029

Keywords

This article is cited by

Search

Quick links